

ESK-001, a novel allosteric, highly selective oral TYK2 inhibitor in development for treatment of immune-mediated disorders, was well-tolerated, and achieved high levels of target inhibition in ...

Most recently, Ms. Thorell served as the Chief Financial Officer of Evelo Biosciences. Prior roles include Chief Accounting Officer at Centessa Pharmaceuticals, Chief Financial Officer of ...

Evelo Biosciences, Inc. (NASDAQ:EVLO - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Stock investors acquired 1,885 put options on the company. This ...

Der Höchststand, in den letzten 52 Wochen, der Evelo Biosciences Aktie lag bei 0,0621 USD (am 26.02.25). Laut aktuellem Kurs ist die Evelo Biosciences Aktie -91,95 % vom ...

Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act ...

The share float percentage for the stock currently stands at 58.74%. There are 52.97% institutions holding the Caribou Biosciences Inc stock share, with BLACKROCK INC. the top institutional ...

Evelo Biosciences, Inc. (EVLO +0%) Evelo is concentrating on inflammatory diseases, as it is now documented that gut health is tightly linked to inflammatory syndromes. The current focus is on skin diseases, psoriasis, and ...



Evelo biosciences inc stock

Web: <https://kindanewdecor.co.za>

